CNO Financial Group, Inc.

CNO Financial Group, Inc. (CNO) Market Cap

CNO Financial Group, Inc. has a market capitalization of .

No quote data available.

CEO: Gary Chandru Bhojwani

Sector: Financial Services

Industry: Insurance - Life

IPO Date: 2003-09-10

Website: https://www.cnoinc.com

CNO Financial Group, Inc. (CNO) - Company Information

Market Cap: -|Sector: Financial Services

Company Profile

Headquartered in Carmel, Indiana, and established in 1979, CNO Financial Group, Inc. operates across the United States, developing, marketing, and administering a broad spectrum of insurance and annuity products primarily for middle-income and senior individuals. The company's health insurance offerings span Medicare supplement plans, various supplemental health coverage (such as specified disease, accident, and hospital indemnity products), long-term care policies, and Medicare Advantage plans. CNO also underwrites a full suite of life insurance products, encompassing universal life, interest-sensitive options, and traditional policies like whole life, graded benefit life, term life, and single premium whole life. For wealth accumulation and retirement income, CNO provides an array of annuities, including fixed index, fixed interest (single and flexible premium deferred), and single premium immediate annuities, often catering to retirees and older self-employed individuals within the middle-income demographic. CNO employs a multi-channel approach to reach its diverse clientele. Individual customers can access products directly through phone, online platforms, mail, or face-to-face interactions. Additionally, the firm cultivates relationships with businesses, associations, and other membership groups, facilitating worksite and group sales by engaging with potential clients at their workplaces. These offerings are distributed through a robust network of agents, independent producers, and direct marketing efforts, promoted under the well-recognized brand names of Bankers Life, Washington National, and Colonial Penn.

Analyst Sentiment

56%
Buy

From 6 Active Polls

1Y Forecast: $51.50

▲ +0.0% Potential Upside

Consensus Target Metrics

Low Bound

$48

Median

$52

High Bound

$55

Average

$52

Price & Moving Averages

Loading chart...

🎯 Wall Street Analyst Intelligence Report

1-Year structural target targets, chart projections, and sentiment maps.

Average 1Y Target
$51.50
▼ -6.52% Upside
Low Target
$48.00
-13% Risk
Median Target
$51.50
-7% Mid
High Target
$55.00
-0% Max

Consensus Trend Projection

Trailing closures vs. 12-month metrics map.

Analyst Vote Distribution

Aggregate institutional coverage sentiment weights.

Sentiment volume allocation data unavailable.

Historical valuation matrix unavailable.

📘 Full Research Report

ℹ️

AI-Generated Research: This report is for informational purposes only.

📘 CNO FINANCIAL GROUP INC (CNO) — Investment Overview

🧩 Business Model Overview

CNO is an insurance and retirement-services company focused on serving pre- and post-retirement customers, primarily through life, annuity, and Medicare-related health products. The business operates by (1) underwriting and pricing risk (mortality, morbidity, lapse/persistency), (2) collecting premiums and policyholder funds, (3) investing those funds in a diversified portfolio of high-quality assets, and (4) paying claims/benefits over the life of the policy. Profitability is driven by the spread between the yield earned on the general account and the cost of policyholder obligations, after underwriting/expense impacts and reserve development.

💰 Revenue Streams & Monetisation Model

Revenue and earnings generation are largely characterized by insurance cash flows and investment income rather than transaction volumes. Core monetisation channels include:

  • Net investment income: a recurring component driven by asset yields and credit quality, net of investment expenses and hedging/derivative activity (where applicable).
  • Insurance-related margins: spread economics and underwriting results on life and health products, including mortality/morbidity and persistency.
  • Policy fees and contract charges: for annuities and related retirement contracts, including account-based charges where contract design permits.

Margin drivers are primarily (a) the cost of policyholder liabilities (including lapse experience), (b) asset-liability management and the level of reinvestment yields, and (c) disciplined underwriting and claims management. For annuity-heavy models, surrender charges and product design can support persistency, improving the durability of investment spread capture.

🧠 Competitive Advantages & Market Positioning

CNO’s moat is best understood as a combination of insurance economics (liability cost management and asset-liability discipline) and distribution-linked switching frictions (persistency and contract terms).

  • Switching Costs / Persistency Effects (Annuities and Health): many retirement products incorporate surrender charges, declining early-withdrawal economics, and contract-specific terms that discourage rapid switching. For Medicare-related insurance, guaranteed-issue structures and underwriting rules shape customer behavior, supporting stable renewal patterns when products remain competitive.
  • Regulatory Moat / Capital Discipline: insurance is a capital-constrained business. State regulation, reserve requirements, risk-based capital frameworks, and statutory reporting create structural barriers that deter unseasoned entrants and constrain balance-sheet risk-taking.
  • Credit Culture and Underwriting Capability: durable results depend on underwriting accuracy and ongoing reserve adequacy, as well as careful general account credit selection. Competence here reduces earnings volatility and supports continued business writing.
  • Operational and Distribution Scale: CNO benefits from repeatable distribution and servicing processes suited to its customer base, which can lower per-policy acquisition and servicing costs relative to smaller or less specialized peers.

Competitive benchmarking (primary peers):

  • Lincoln Financial Group (LNC): broader life/annuity product set with strong retirement franchises; positioned differently across channels and product mix compared with CNO’s Medicare-focused health exposure and retirement contract mix.
  • Brighthouse Financial (BHF): emphasizes annuities and retirement solutions; competes for similar retirement-income demand, but the competitive vector differs where CNO’s Medicare supplement-related business changes the mix of risk and earnings drivers.
  • Mutual of Omaha (MOH): a prominent player in senior-focused insurance products; competes for Medicare-related customer segments, where CNO’s product design and underwriting/distribution approach aim to win persistency and profitability rather than simply maximize volume.

🚀 Multi-Year Growth Drivers

Over a 5–10 year horizon, CNO’s growth opportunity is anchored in demographic and retirement-income themes that support steady demand for insurance-based income solutions:

  • Age-Driven TAM expansion: the aging population sustains long-run demand for Medicare-related coverage and retirement products designed to provide lifetime or structured income.
  • Retirement income transition: households increasingly seek to convert retirement savings into more predictable income streams, supporting annuity and related retirement contract demand.
  • Persistency-led compounding: in insurance, durable earnings often compound through persistency and reinvestment of policyholder funds, not just new sales volume.
  • Premium and contract optimization: active portfolio management—product design, underwriting discipline, and asset-liability management—can improve risk-adjusted returns even when industry growth is moderate.

⚠ Risk Factors to Monitor

  • Interest rate and spread risk: insurance earnings can be pressured by sustained changes in yield curves, reinvestment rates, or the cost characteristics of liabilities; effective asset-liability management is critical.
  • Credit and market-value risk: deterioration in bond credit quality or wider credit spreads can affect investment income and impair the earnings power of the general account.
  • Regulatory and pricing risk (Medicare-related and insurance regulation): rate-setting frameworks, solvency rules, and compliance requirements can limit the ability to pass through costs or restructure reserves.
  • Longevity and morbidity variability: mortality and health claim experience can diverge from expectations, requiring reserve actions and disciplined product pricing.
  • Liquidity and capital adequacy: stress scenarios test statutory capital, dividend capacity, and the balance between growth and risk-based capital consumption.

📊 Valuation & Market View

Insurance equity valuation tends to focus less on simple operating multiples and more on balance-sheet quality and embedded earning power. Market participants typically anchor on:

  • Price-to-book and book value durability: how earnings translate into statutory and book value growth.
  • Earnings quality: persistence of investment spread and underwriting discipline, alongside reserve development credibility.
  • Embedded value / capital efficiency (framework-dependent): the degree to which new business and existing policy blocks translate into durable shareholder value given capital constraints.
  • Sensitivity to rates and credit: valuation often moves with expected future yields, credit spreads, and the perceived risk of reserve or capital strains.

Key drivers that move the needle are typically changes in expected investment yields, credit outlook, reserve adequacy confidence, and the ability to maintain persistency while competing on pricing and product terms.

🔍 Investment Takeaway

CNO’s long-term investment case rests on an insurance-focused moat: stable policyholder economics supported by persistency, regulatory-capital barriers, and operational underwriting/investment discipline. The business can compound through durable investment spread capture and demographic tailwinds for Medicare- and retirement-related products, provided credit quality, reserve adequacy, and asset-liability management remain intact through rate and credit cycles.


⚠ AI-generated — informational only. Validate using filings before investing.

📊 AI Financial Analysis

Powered by StockMarketInfo
Earnings Data: Q Ending 2026-03-31

"CNO reported Q1 2026 results with Revenue of $1.03B and Net Income of $37.7M (EPS $0.40). On an annual basis (vs. Q1 2025), revenue declined by -2.4% YoY ($1.03B vs. $1.00B) while net income increased by +175.5% YoY ($37.7M vs. $13.7M). Sequentially (vs. Q4 2025), revenue fell by -9.9% QoQ ($1.15B to $1.03B) and net income fell by -59.4% QoQ ($92.9M to $37.7M). Profitability improved materially versus a year ago: net margin increased to 3.7% from 1.4% YoY, but operating and net margins were lower than Q4. Gross margin rose to 44.6% from 35.2% YoY, yet the company’s QoQ profit compression is evident—net margin dropped from 8.1% in Q4 to 3.7% in Q1. Balance sheet resilience appears reasonable for a financial services insurer: total assets were $38.9B, with equity at $2.50B, broadly stable QoQ ($2.64B in Q4), and long-term debt at $4.30B. Cash flow metrics are presented as 0 for Q1 due to dataset limitations, so quarter-level cash generation quality cannot be confirmed here; however, dividends were not paid in Q1 (payout dynamics look variable). Shareholder returns based on the provided market data were solid: the stock is up +14.6% over 1Y (below the 20% momentum threshold). Total value drivers thus look more valuation/earnings execution than outsized momentum, while analyst targets imply modest upside (consensus $46.67 vs. ~$43.63)."

Revenue Growth

Caution

Revenue was $1.03B in Q1 2026: -2.4% YoY and -9.9% QoQ, indicating a contracting top line sequentially.

Profitability

Positive

Net margin improved sharply YoY (3.7% vs. 1.4%), but profitability contracted QoQ (net margin 3.7% vs. 8.1% in Q4). EPS was $0.40 vs. $0.14 YoY.

Cash Flow Quality

Fair

Q1 cash flow fields show net cash from operating activities as 0 in the dataset, limiting assessment of cash generation quality; dividends were 0 in Q1.

Leverage & Balance Sheet

Positive

Total assets were $38.9B with equity around $2.50B; long-term debt was $4.30B. Leverage appears manageable, though equity slipped QoQ.

Shareholder Returns

Neutral

1Y price gain is +14.6% (not >20% momentum). Dividend yield is ~0.44% per the provided ratio; buybacks are not captured in Q1.

Analyst Sentiment & Valuation

Neutral

Consensus target ($46.67) is above the current price (~$43.63), implying modest upside; valuation implies expectations of ongoing profitability normalization.

Disclaimer:This analysis is AI-generated for informational purposes only. Accuracy is not guaranteed and this does not constitute financial advice.

Fundamentals Overview

Loading fundamentals overview...

CNO delivered a strong Q2 2026 led by operating EPS of $1.26 (+45% YoY) and continued sales momentum (new annualized premiums +7%). The earnings engine is broad: favorable underwriting, block growth across fixed indexed annuities, Medicare supplement, and long term care, and rising net investment income (+8% YoY) with a new money rate of 6.16% and a 14th straight quarter above 6%. Management raised 2026 operating EPS guidance to $4.60–$4.80 (+8% at midpoint) and narrowed the expense ratio to 18.8%–19.0% (20 bps lower at the top end), while lowering the effective tax rate assumption to ~21.5%. Key Q&A themes centered on how durable reserve-driven margin improvements are (MedSup ~$4 million reserve development) and whether long term care claims remain structurally better (to be assessed in the Q3 annual review). Capital actions ($60 million buybacks) continue alongside early Tech Mod reinvestment and Bermuda initiatives subject to regulatory approval.

AI IconGrowth Catalysts

  • Operating EPS up 45% YoY on improving insurance product margin and stronger net investment income, supporting elevated full-year guidance
  • Consumer: Total Health NAP up 17% (16 consecutive quarters); Medicare Supplement NAP up 52% (third consecutive quarter over 50%) driven by preference shift from Medicare Advantage to supplements
  • Worksite: Record life and health NAP up 29%; life up 44%, hospital indemnity up 33%, accident up 31%, critical illness up 7%; NAP from new clients up 84%
  • Discipline in D2C life marketing mix: non-television channels (web/digital/third-party partners) generated ~72% of all D2C life sales while reducing TV reliance
  • Insurance margin tailwinds from favorable underwriting and reserve releases (supplemental health and Medicare supplement), plus block growth across fixed indexed annuities, long term care, and life

Business Development

  • Named partners/customers: none explicitly named in the transcript
  • Distribution/partner-related mention: third-party partners used in D2C life marketing (no firm names provided)

AI IconFinancial Highlights

  • Operating earnings per diluted share: $1.26, up 45% YoY in Q2 2026
  • Operating EPS YTD: up 43% YoY excluding significant items
  • Total new annualized premiums: up 7% and multiple sales records achieved
  • Insurance product margin: growth across all three major categories supported by favorable underwriting and reserve developments; Medicare supplement benefited from favorable morbidity and rate increases earlier in 2026
  • Expense ratio: 18.4% (favorable); company views as timing and expects normalization later in 2026
  • Net investment income: up 8% YoY; 11th consecutive quarter of growth; new money rate 6.16% and 14 consecutive quarters above 6%
  • Investment income allocated to product lines: up 3% supporting growth in average net insurance liabilities (+4%)
  • Net investment income not allocated to products: improved 46% YoY driven by higher alternative investment income (including $300 million FABN issuance in Q2) and higher gains on option forfeitures from annuity surrenders
  • Capital and balance sheet: consolidated RBC ratio 377%; holding company liquidity $233 million; debt to capital 26.1%
  • Tax guidance: effective tax rate assumption lowered to ~21.5% for 2026 guidance

AI IconCapital Funding

  • Share repurchases: $60 million in the quarter; weighted-average diluted shares reduced ~5%
  • Return to shareholders: $77 million total in the quarter (includes dividends and/or repurchases as characterized by management)
  • Capital management posture: capital deployed after meeting target capital levels and holdco liquidity; no change in leverage/RBC targets
  • Free cash flow: full-year expectations reaffirmed; management expects to move closer to target capital levels at operating subsidiaries (including Bermuda) contributing to second-half free cash flow subject to regulatory approvals

AI IconStrategy & Ops

  • Tech Mod initiative: referenced as significant early-stage reinvestment to update core applications/infrastructure and reduce risk/position for growth
  • Expense normalization expectation: expense ratio timing benefit in first half; guided expense ratio narrowing to 18.8%–19.0% full-year
  • Consumer D2C channel optimization: reduced reliance on television advertising; shift toward web/digital/third-party partner mix (nearly 72% of D2C life sales this quarter)
  • Worksite channel strategy: optimized career agency expected to remain a major growth engine (~90% of total worksite insurance sales); continuing to invest to expand this channel

AI IconMarket Outlook

  • 2026 operating EPS guidance increased to $4.60–$4.80 (8% increase at midpoint vs prior guidance)
  • 2026 expense ratio guidance narrowed to 18.8%–19.0% (upper end reduced by 20 bps reflecting improved operating leverage)
  • 2026 effective tax rate assumption: lowered to ~21.5%
  • Management reaffirmed: RBC ratio target, holdco liquidity target, leverage targets, and full-year free cash flow expectations
  • ROE outlook: 2026 operating ROE expected to exceed previously stated 3-year target of 12% for year-end 2027; new ROE targets planned for February 2027

AI IconRisks & Headwinds

  • Long term care margin sustainability uncertainty: management observes modestly lower claims vs expectations and will reassess during annual review in Q3
  • MedSup reserve development may not recur: reserve release sized at ~$4 million (claims reserves develop quickly); adjusted run-rate guidance implied for future margin trajectory
  • Life sales not linear: management acknowledged lifecycle volatility and potential Q3 variability versus Q2 due to comps
  • Industry annuity competition/arms race: noted new entrants and competitive pressure; however management believes captive distribution and middle-income focus insulate results
  • Regulatory approval dependency: capital/liability seeding plans (including potential Bermuda treaty-related actions) depend on regulatory approvals

Q&A: Analyst Interest

  • Long Term Care sustainability: Management said margins are reviewed each quarter and more thoroughly in Q3 as part of the annual review. They observed modestly lower claims versus expectations, within the favorable range of current assumptions. They declined to pre-judge sustainability until the third-quarter exercise and reporting.
  • MedSup reserve release sizing and margin trajectory: Management attributed the observed MedSup margin step-up to favorable claims reserve development that was around $4 million, noting reserves develop quickly. They recommended adjusting for that item when thinking about run-rate, and said the first half combined picture better indicates expected forward margins.
  • Capital deployment and Bermuda/block movement timing: Management reiterated capital deployment priorities are unchanged, citing ongoing Tech Mod investment and the aim to return capital after reaching target capital/holdco liquidity. For Bermuda and moving blocks, they would not provide details or excess capital figures, emphasizing regulatory approvals and “stay tuned” updates.

Sentiment: POSITIVE

Note: This summary was synthesized by AI from the CNO Q2 2026 earnings transcript. Financial data is complex; please verify all metrics against official SEC filings before making investment decisions.

Loading financial data and tables...
© 2026 Stock Market Info — CNO Financial Group, Inc. (CNO) Financial Profile